• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.

作者信息

Tefferi Ayalew, Letendre Louis

机构信息

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Am J Hematol. 2011 Jul;86(7):610-1. doi: 10.1002/ajh.22051. Epub 2011 May 31.

DOI:10.1002/ajh.22051
PMID:21630307
Abstract
摘要

相似文献

1
Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.尼罗替尼治疗相关的外周动脉疾病和猝死：坚持将伊马替尼作为慢性髓性白血病一线治疗药物的又一理由。
Am J Hematol. 2011 Jul;86(7):610-1. doi: 10.1002/ajh.22051. Epub 2011 May 31.
2
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy.
Am J Hematol. 2011 Jul;86(7):531-2. doi: 10.1002/ajh.22084. Epub 2011 Jun 14.
3
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.尼洛替尼治疗 CML 期间进展性外周动脉闭塞性疾病和其他血管事件。
Am J Hematol. 2011 Jul;86(7):533-9. doi: 10.1002/ajh.22037. Epub 2011 Apr 27.
4
Severe peripheral arterial disease during nilotinib therapy.尼洛替尼治疗期间出现严重外周动脉疾病。
J Natl Cancer Inst. 2011 Sep 7;103(17):1347-8. doi: 10.1093/jnci/djr292. Epub 2011 Aug 2.
5
NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.英国国家卫生与临床优化研究所（NICE）针对对伊马替尼耐药或不耐受的慢性粒细胞白血病（CML）患者使用达沙替尼、高剂量伊马替尼和尼罗替尼的指南。
Lancet Oncol. 2012 Feb;13(2):127-8. doi: 10.1016/s1470-2045(12)70008-6.
6
Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.一线伊马替尼治疗延迟启动预示着对尼洛替尼作为伊马替尼耐药或不耐受慢性粒细胞白血病二线治疗的反应不佳：黎巴嫩ENACT试验的单中心报告
Int J Hematol. 2012 Oct;96(4):521-4. doi: 10.1007/s12185-012-1168-9. Epub 2012 Sep 9.
7
Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.尼罗替尼治疗慢性粒细胞白血病：对BCR/ABL的高选择性优势
Curr Drug Targets. 2009 Jun;10(6):530-6. doi: 10.2174/138945009788488468.
8
Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.在伊马替尼治疗慢性骨髓增殖性疾病期间发生的骨髓纤维化，该疾病同时存在BCR-ABL易位和JAK2V617F突变。
Blood. 2007 May 1;109(9):4106-7. doi: 10.1182/blood-2006-12-061135.
9
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.尼洛替尼与伊马替尼治疗新诊断的费城染色体阳性慢性期慢性髓性白血病患者：3 期随机 ENESTnd 试验的 24 个月最小随访。
Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17.
10
Chronic myeloid leukemia: where do we go now?慢性髓性白血病：我们现在何去何从？
Clin Lymphoma Myeloma. 2009;9 Suppl 4:S374-5. doi: 10.3816/CLM.2009.s.036.

引用本文的文献

1
Haematological Drugs Affecting Lipid Metabolism and Vascular Health.影响脂质代谢和血管健康的血液学药物
Biomedicines. 2022 Aug 10;10(8):1935. doi: 10.3390/biomedicines10081935.
2
The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.第二代和第三代BCR-ABL酪氨酸激酶抑制剂治疗慢性髓性白血病患者的动脉血栓形成风险可能与其对内皮细胞的影响有关：一项体外研究。
Front Pharmacol. 2020 Jul 3;11:1007. doi: 10.3389/fphar.2020.01007. eCollection 2020.
3
Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.
BCR-ABL1酪氨酸激酶抑制剂的心脏毒性：重点关注波纳替尼。
Int J Cardiol. 2020 Oct 1;316:214-221. doi: 10.1016/j.ijcard.2020.05.077. Epub 2020 May 27.
4
Vascular toxic effects of cancer therapies.癌症治疗的血管毒性作用。
Nat Rev Cardiol. 2020 Aug;17(8):503-522. doi: 10.1038/s41569-020-0347-2. Epub 2020 Mar 26.
5
Dasatinib Inhibits Procoagulant and Clot Retracting Activities of Human Platelets.达沙替尼抑制人血小板的促凝和血栓回缩活性。
Int J Mol Sci. 2019 Oct 31;20(21):5430. doi: 10.3390/ijms20215430.
6
Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study.接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的外周动脉闭塞性疾病：一项横断面病例对照研究
Clin Med Insights Cardiol. 2017 Dec 15;11:1179546817747258. doi: 10.1177/1179546817747258. eCollection 2017.
7
SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions.干细胞因子-干细胞因子受体信号传导诱导内皮素-3的合成与分泌：从而激活并调节内皮素B受体，以产生时间和空间精确的一氧化氮来调节表达干细胞因子和/或干细胞因子受体的细胞功能。
PLoS One. 2017 Sep 7;12(9):e0184154. doi: 10.1371/journal.pone.0184154. eCollection 2017.
8
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.尼罗替尼诱发的血管病变：确定血管内皮细胞为主要靶位点。
Leukemia. 2017 Nov;31(11):2388-2397. doi: 10.1038/leu.2017.245. Epub 2017 Jul 31.
9
Management of CAD in Patients with Active Cancer: the Interventional Cardiologists' Perspective.活跃期癌症患者冠心病的管理：介入心脏病学家的观点
Curr Cardiol Rep. 2017 Jun;19(6):56. doi: 10.1007/s11886-017-0862-x.
10
Ischemic Heart Disease: Special Considerations in Cardio-Oncology.缺血性心脏病：心脏肿瘤学中的特殊考量
Curr Treat Options Cardiovasc Med. 2017 May;19(5):37. doi: 10.1007/s11936-017-0535-5.